0001209191-22-018021.txt : 20220310
0001209191-22-018021.hdr.sgml : 20220310
20220310180016
ACCESSION NUMBER: 0001209191-22-018021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220308
FILED AS OF DATE: 20220310
DATE AS OF CHANGE: 20220310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BALDO LANCE
CENTRAL INDEX KEY: 0001780773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 22730349
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-08
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780773
BALDO LANCE
1165 EASTLAKE AVENUE E
SEATTLE
WA
98109
0
1
0
0
Chief Medical Officer
Common Stock
2022-03-08
4
S
0
3350
11.43
D
17171
D
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.28 to 11.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
/s/ Lance Baldo by Eric Billings, attorney-in-fact
2022-03-10